New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
04:55 EDTPFE, PFE, VRTX, VRTX, BAYRY, BAYRY, CBST, CBST, IRWD, IRWD, AMGN, AMGN, SHPG, SHPG, GSK, GSK, CELG, CELG, BMY, BMY, LLY, LLYQ1 Productions to hold a conference
Customer Centric Medical Information Conference to be held in Boston on June 26-27.
News For PFE;BMY;CELG;GSK;SHPG;AMGN;IRWD;CBST;BAYRY;VRTX;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
September 19, 2014
16:00 EDTPFEOptions Update; September 19, 2014
Subscribe for More Information
10:07 EDTPFEHigh option volume stocks
Subscribe for More Information
07:35 EDTBAYRYZoetis seen as potential Bayer target after split announcement, Bloomberg says
Subscribe for More Information
05:58 EDTGSKGlaxoSmithKline to pay GBP 297M fine to Chinese government
Subscribe for More Information
September 18, 2014
15:57 EDTLLYFDA approves Trulicity with boxed warning, post-marketing study requirements
Subscribe for More Information
15:55 EDTLLYFDA approves Eli Lilly type 2 diabetes drug
Subscribe for More Information
11:15 EDTLLYRepros sinks after panel backs tests for testosterone therapies
Subscribe for More Information
08:12 EDTLLYEli Lilly's Cyramza for gastric cancer shows positive Phase 3 results
Eli Lilly announced results of the global Phase III trial of ramucirumab - CYRAMZA - in combination with paclitaxel in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma. The addition of ramucirumab to paclitaxel showed a statistically significant improvement in median overall survival, meeting its primary endpoint; it also met secondary endpoints of progression-free survival and objective response rate. Data from the trial were first presented in January. Ramucirumab has now been the focus of two positive Phase III gastric cancer trials that have demonstrated statistically significant improvements in both overall survival and progression-free survival.
08:01 EDTLLYDow AgroSciences announces R&D agreement with Lilly's Elanco
Two Indiana agricultural companies, Elanco, the animal health division of Eli Lilly and Company (LLY), and Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (DOW), are announcing a strategic research and development agreement that will focus on developing integrated solutions to enable livestock producers to increase meat and milk production to meet the demands of the growing global population.
07:24 EDTVRTXVertex management to meet with Deutsche Bank
Subscribe for More Information
06:20 EDTBAYRYBayer to float MaterialScience as separate company
Subscribe for More Information
06:10 EDTLLYFDA panel votes 20-1 to study changes to testosterone therapies
Subscribe for More Information
05:33 EDTCBSTCubist opens international headquarters in Zurich, will invest $400M in R&D
Subscribe for More Information
September 17, 2014
17:44 EDTBAYRYBayer plans separation of MaterialsSciences unit, WSJ says
Subscribe for More Information
14:57 EDTGSKProsensa announces commencement of re-dosing of drisapersen
Subscribe for More Information
08:03 EDTAMGNAmgen price target raised to $151 from $143 at Morgan Stanley
Morgan Stanley raised Amgen's price target to $151 based on increased brodalumab and AMG 416 expectations. Shares are Overweight rated.
07:43 EDTBMY, PFE, SHPGBofA/Merrill to hold a conference
Subscribe for More Information
07:39 EDTGSK, LLYMorningstar to hold a conference
Management Behind the Moat Conference to be held in Chicago on September 17-18.
07:09 EDTVRTXVertex price target raised to $127 from $103 at Deutsche Bank
Subscribe for More Information
07:00 EDTCELGConcert Pharmaceuticals announces initiation of CTP-730 Phase 1 trial
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use